Abstracts Clinical Lymphoma, Myeloma & Leukemia September 2023 S264 cytometry in 30 newly diagnosed patients with AML. The patients were recruited from a clinical hematology department at Ain Shams University Hospital from May 2017 to November 2018. Results: A total number of 30 patients with AML were recruited from Ain Shams University Hospital, Hematology and Oncology Unit Outpatient Clinic, with age ranging from 18-60 years (median age 40 years), 14 of whom were males, representing 46.6% of the total number and 16 females, representing 53.3% of the total number. There was no statistical significance between the age of the studied group and the MRD, with a P value of 0.147; the sex of the patients did not contribute to the risk stratification, with a P value of 0.200. The number of patients with negative MRD after induction was 13, representing 43.3% of the total number, and it was 12 patients after 6 months, representing 70.5% of the remitted patients, considering that the cut-out value of MRD is 0.1. There was a significant relationship between total leukocyte count (TLC) and MRD; the higher the TLC, the more positive the MRD. Positive MRD is associated with higher mortality rates, exhibiting statistical significance with a P value of 0.005. Conclusion: We concluded that assessment of MRD in AML is of great value in determination of prognosis of the disease and its outcome, and it is of great value to determine the levels of MRD during the course of therapy and to stratify patients to identify high-risk patients and to plan the therapeutic program accordingly. Keywords: acute myeloid leukemia, minimal residual disease, phase III AML-055 Correlation Between CD200 Expression on Leukemic Stem Cells and Response to Treatment in De novo Adult Acute Myeloid Leukemia Patients Nouran Hassan BS, Tamer Ibrahim MD, Nermeen Nabeeh MD, Rana Abdelfatah MD Faculty of Medicine, Ain Shams University, Cairo, Egypt Context: CD200 is the ligand for the CD200 receptor (CD200R) that is expressed on myeloid and lymphoid cells, and it is considered an important immunological checkpoint that subsequently inhibits anti-tumour immune responses. In this study, we aimed to study the relationship between CD200 and the response outcome to induction therapy in Egyptian adult acute myeloid leukemia (AML) patients. Objectives: To assess the expression of CD200 in leukemic stem cells and its impact on response to induction therapy in adult patients with AML. Design: This crosssectional study was conducted in the Adult Clinical Hematology Department at Ain Shams University Hospitals between May 2021 to December 2022. Patients and Methods: The study included 68 newly-diagnosed adult AML patients. Blood samples were collected from each patient at the time of diagnosis and during assessment of response to induction therapy. Main Outcome Measures: Beside the basic investigations, fluorescence flow cytometry was performed in order to analyze CD200 protein expression on samples from AML patients. Results: CD200 expression ranged from 1.3 to 92.8, with a mean standard deviation of 49.20±34.61. Nineteen patients (27.9%) were “negative CD200” and 49 patients (72.1%) were “positive CD200.” The higher positive CD200 levels were found in the non-responder group of 31 patients (100%) compared to the responder group of 18 patients (48.6%). Meanwhile, there was a statistically significant difference (P<0.001) between the responder and non-responder groups, according to CD200 level. Conclusion: CD200 expression in myeloid blasts of AML patients could play a role in the development of AML. Analysis of this marker could serve as a prognostic marker and might guide the therapy in AML patients in the future. Keywords: AML, CD200, myeloid, leukemia, de novo AML-066 Safety and Efficacy of FLAG‑IDA‑Based Therapy Combined With Venetoclax for the Treatment of Newly Diagnosed and Relapsed/Refractory Patients With AML: A Systematic Review Adi Sherban MD1,2,3, Danielle Fredman MD1,2, Shai Shimony MD2,3,4, Moshe Yeshurun MD2,3, Pia Raanani MD3,2, Maximillian Stahl MD4, Anat Gafter-Gvili MD1,2,3, Ofir Wolach MD2,3 1Internal Medicine Department A, Rabin Medical Center, Petach Tikva, Israel. 2Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel. 3Institute of Hematology, Davidoff Cancer Center, Rabin Medical Center, Beilinson Hospital, Petach Tikva, Israel. 4Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, USA Context: Venetoclax (VEN) in combination with intensive chemotherapy (IC) is increasingly used to treat patients with highrisk acute myeloid leukemia (AML). We conducted a systematic review to assess the safety and efficacy outcomes of FLAG-IDA in combination with VEN. Methodology: The primary safety outcome was infections; the primary efficacy outcome was response to treatment (composite complete remission [CRc] and overall response rate [ORR]). Risk of bias was assessed according to the ROBINS-I tool. Results: Six studies and 221 patients with newly diagnosed (ND) (n=120)) and R/R AML (n=101) disease were included in this systematic review. Pooling of results was not conducted due to major differences between studies. The reported rates of neutropenic fever, bacteremia, pneumonia, and invasive fungal infections were at 44-55%, 24-48%, 12-30% and 11-36% of assessed patients, respectively. Time to ANC and platelet recovery ranged between 23-29 and 23-31 days, respectively. Early death was reported in 9.5% of patients. CRc rates ranged between 53% and 78% for R/R AML. CRc for ND was reported by one study only (89%). ORR were reported in 60% to 78% of patients with R/R AML. Only one study reported an ORR for ND patients of 98%. Conclusion: In our systematic review, FLAG-IDA plus VEN proved to be a tolerable and effective regimen in ND and R/R AML patients. We suggest further evaluation and confirmation for the safety and efficacy of this new protocol in future RCTs. Keywords: AML, venetoclax, FLAG-IDA
RkJQdWJsaXNoZXIy MTk3NTQxMg==